Compare Inovio Pharmaceuticals Inc (INO) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Southern Copper Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M), while Southern Copper Corp trades at $194.56 (market cap $164.21B). The key difference: Southern Copper Corp is far larger — about 2090.5× Inovio Pharmaceuticals Inc's market cap, and Southern Copper Corp pays a 2.26% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SCCO | |
|---|---|---|
Market Cap | $78.55M | $164.21B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $218.85 |
52-Week Low | $0.66 | $93.70 |
Enterprise Value | $49.56M | $165.50B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Southern Copper (SCCO) trades at $194.86, down 2.62% on the day, with a bullish technical signal from moving averages and strong support at $191. The company reported record Q2 2026 earnings, beating estimates with EPS of $1.99, driven by high metal prices, though production volumes declined. Revenue and net income have grown consistently, with 2025 revenue at $13.42B and net income at $4.33B, reflecting a net margin of 35.87%.
Outlook remains positive due to robust profitability and AI-driven copper demand, but risks include premium valuation (P/E 29.18), reliance on metal prices, and mixed analyst sentiment with a consensus price target of $153.64 below current levels. Institutional buying and strong cash flow trends support growth, yet investors face volatility from commodity cycles and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
